Wading into the Valeant Pharmaceuticals investment debate

June 12, 2016 | Posted by admin

By Richard Jennings, CFA There have been innumerable articles and countless words written about the implosion of Valeant Pharmaceuticals (VRX) in recent months with the story surrounding the so called “price gouging” (acquiring companies with drug portfolios and jacking up the price to patients by material amounts) and the issue over the company’s circa $30bn […]